- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06093815
Prospektiv studie for å vurdere vevsresponser etter injeksjon med biostimulerende produkter
Prospektiv, kontrollert sammenlignende studie på enkelt sted for å identifisere og vurdere vevsresponser etter injeksjon med forskjellige biostimulerende produkter
The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study.
Safety endpoint: incidence of adverse events.
Studieoversikt
Detaljert beskrivelse
The objective of this study is to identify and assess tissue responses after injection with various biostimulatory products that are already used in the market and have CE approval. The study will assess in vivo tissue responses and provide tissue specimens which will be used in a subsequent study, under a separate protocol.
Assessments under this protocol will include ultrasound of in vivo tissue.
Safety endpoint: incidence of adverse events.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Marbella, Spania
- Ocean Clinic - Av. Ramon y Cajal 7, 29601
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Healthy male & females; 22 to 65 years of age.
- Voluntary participation
- Ability to comprehend and provide informed consent.
- Participants agree NOT to use any topical agents or products that will induce skin peeling or change the appearance of the skin in the treatment area, during the study period.
- Participants agree NOT to undergo any aesthetic treatments that influence the appearance of the skin in the treatment area during the study period.
- Participants agree NOT to undergo any surgical treatments in the treatment area during the study period.
- Participants agree NOT to take part in another clinical study or undergo other treatments during the study period.
Exclusion Criteria:
- Any previous surgery in the abdominal area.
- Any previous treatment in the abdominal area.
- Planning to receive treatment of any kind in the abdominal area.
- Acute inflammatory process and/or infection at the injection site.
- Treatment of skin area with dermatosis.
- Eczema, exanthema or open wounds.
- Previous application of over the counter or prescription, oral or topical, anti-wrinkle or skin enhancer products on the abdominal skin within the past 3 months unless allowed by the study and is continued throughout the study.
- Any contraindication to treatment with biostimulatory products based on the product's IFU.
- Previous pregnancy or intending to become pregnant during study participation.
- Known hypersensitivity to biostimulatory products or any of their formulation ingredients.
- Allergic reaction to topical and local anesthetics.
- Currently using anticoagulant therapy.
- Haemophilia / bleeding disorder.
- Chemotherapy, radiotherapy or high doses of corticosteroids.
- Systemic infection (e.g., hepatitis).
- Uncontrolled diabetes mellitus.
- Any medical condition that may put the participant at increased risk with exposure to biostimulatory products.
- Any medication that might modulate the immune response.
- Any other illness or condition that, in the opinion of the investigator, would mean that study participation was not in the best interest of the prospective participant.
- Is a female of childbearing potential and not using medically effective birth control or is pregnant or lactating.
- Any serious disease or disorder (medical or psychiatric) that could, in the opinion of the investigator, interfere with the safe completion of treatment according to this protocol or with study.
- Injection of local anesthesia into the flap during abdominoplasty surgery.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm 1
Subjects in Arm 1 will receive injections of biostimulatory products (Radiesse(+) undiluted, Radiesse diluted 1:1, Radiesse diluted 1:2, Sculptra, Ellanse, HArmonyCa) at 3 timepoints (six months, three months and two weeks) prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Eksperimentell: Arm 2 - Radiesse Classic (1:1 Dilution)
Five participants in Arm 2 will receive Radiesse Classic diluted 1:1 with sterile saline (CaHA-CMC 1:1) and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Eksperimentell: Arm 2 - Sculptra
Five participants in Arm 2 will receive Sculptra diluted with 5 mL of sterile saline and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Arm 1 - Ultrasound Analyses - Skin Thickness (mm)
Tidsramme: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Elastosis
Tidsramme: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Microvascular Formation
Tidsramme: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at the injection site and reported according to the study-defined category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Skin Thickness (mm)
Tidsramme: 6 months prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Elastosis
Tidsramme: 6 months prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Microvascular Formation
Tidsramme: 6 months prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at injection site and reported according to the study-defined category/grade. |
6 months prior to surgery timepoint(s)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety Assessment
Tidsramme: through study completion, an average of 6 months
|
Any patient- or investigator-observed adverse event |
through study completion, an average of 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Ann P Marx, MD, Merz North America, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Kjemisk-induserte lidelser
- Legemiddelrelaterte bivirkninger og uønskede reaksjoner
- Ekstravasering av diagnostiske og terapeutiske materialer
- Patologiske tilstander, tegn og symptomer
- Reaksjon på injeksjonsstedet
- Terapeutikk
- Drug Administration -ruter
- Medikamentell terapi
- Injeksjoner
Andre studie-ID-numre
- M900311010
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
individual data will be summarized for analyses
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .